Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1

Thrombosis and Haemostasis

Volumn 84, Issue 5, 2000, Pages 871-875

  Vleugels, N ^a   Leys, J ^a   Knockaert, I ^a   Declerck, P J ^a  

^a Faculty of Pharmaceutical Sciences   (Belgium)

Author keywords

Mutagenesis; PAI 1; Serpins; Stability

Indexed keywords

DRUG RESIDUE; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR;

ARTICLE; BINDING AFFINITY; CHEMICAL INTERACTION; DIMERIZATION; DRUG CONFORMATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PURIFICATION; DRUG STABILITY; ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

EID: 0033677956     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614130     Document Type: Article

References (29)

1. Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family
2. Cloning and sequence of a cDNA coding for the human beta- migrating endothelial-cell-type plasminogen activator inhibitor
3. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator
4. Structural basis of latency in plasminogen activator inhibitor-1
5. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
6. Molecular evolution of plasminogen activator inhibitor-1 functional stability
7. Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1
8. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1
9. Efficient oligonucleotide-directed construction of mutations in expression vectors by the gapped duplex DNA method using alternating selectable markers
10. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop
11. Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant
12. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop
13. Immunological quantitation of rabbit plasminogen activator inhibitor-1 in biological samples. Evidence that rabbit platelets do not contain PAI-1
14. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms
15. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma
16. Real time biospecific interaction analysis. The integration of surface plasmon resonance detection, general biospecific interface chemistry and microfluidics into one analytical system
17. Type 1 plasminogen activator inhibitor: Conformational differences between latent, active, reactive centre cleaved and plasminogen activator complexed forms, as probed by proteolytic susceptibility
18. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate
19. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor
20. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1
21. Construction and characterization of plasminogen activator inhibitor-1 mutants in which part of the active site loop is deleted
22. Restoration of serine protease-inhibitor interaction by protein engineering
23. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition
24. What do dysfunctional serpins tell us about molecular mobility and disease?
25. Importance of the release of strand 1C to the polymerization mechanism of inhibitory serpins
26. Plasminogen activator inhibitor-1: Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation
27. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion
28. Reaction of human chymase with reactive site variants of alpha 1-antichymotrypsin. Modulation of inhibitor versus substrate properties
29. Structure-function relationship in serpins: Current concepts and controversies